Geron to Provide Stem Cells to GE Unit - 6.30.09
- Geron Corp. agreed to provide stem cells to General Electric Co.'s GE Healthcare for use in tools that test drug treatments for their toxic effects on the body, particularly the heart and liver.
Geron soars on GE stem cell deal - 6.30.09
- Shares of Geron jumped 98 cents, or 15 percent, to $7.67, the greatest gain since May 5. The shares have risen 64 percent this year.
GE Teams With Cloning Company Geron for Embryonic Stem Cell Research - 6.30.09
- General Electric Company is teaming up with Geron, a biotech firm that engages in human cloning, to form what could be the largest embryonic stem cell research conglomerate. The team wants to use the controversial research to determine whether some medicine are toxic.
Ohio Awards Public-Private Stem-Cell Consortium $5M to Help Market Its Discoveries - 6.30.09
- The Center for Stem Cell and Regenerative Medicine, which comprises researchers from Ohio academic institutions, research hospitals, and the private sector, will use the grant to fund nine new research projects this year and at least eight in coming years.
First Clinical Trials Completed of Adult Cardiac Stem Cell Repair - 6.30.09
- Doctors at Cedars-Sinai Heart Institute in Los Angeles have announced the successful completion of the first human trials in growing new heart tissue from adult cardiac stem cells, which the researchers hope will be successful in repairing damage due to heart attacks.
Stem Cell Therapy Safe and Effective - 6.30.09
- Advanced Cell Technology, located in Worcester Massachusetts, reported the results of a long-term study on the safety and efficacy of using human embryonic stem cells to combat retinal diseases like age-related macular degeneration and Stargardt disease.
CEL-SCI Completes $5.85 Million Registered Direct Offering - 6.30.09
- CEL-SCI Corporation (NYSE Amex: CVM), a late stage cancer immunotherapy company, today announced that it has completed a registered direct offering under which it raised gross proceeds of $5.85 million before deducting placement agent fees and estimated offering expenses.
Chief scientist quits California stem-cell agency - 6.30.09
- Marie Csete, a doctor and stem-cell biologist, has resigned from CIRM's top science job, effective from 1 August. The move leaves CIRM without medical leadership as it prepares to issue US$210 million in grants for stem-cell research that aim towards clinical trials. "When it became clear to me that my considered clinical advice was not respected, I concluded that it made no sense for me to stay at CIRM," she says.
More stem cell trial problems for Osiris Therapeutics - 6.30.09
- Clinical trials can be vexing, just ask anyone associated with Osiris Therapeutics, a leading stem cell therapeutic company. The company recently announced that their mid-stage, Phase II trials to treat chronic obstructive pulmonary disease (COPD) with adult stem cells (called Prochymal) did a great job reducing inflammation, but failed to improve pulmonary function.
ReNeuron falls as no news on its stroke treatment - 6.30.09
- Shares in British stem cell specialist ReNeuron fell 10.5 percent on Tuesday after market talk that the day would bring an update on regulatory clearance for its lead stoke treatment proved unfounded.
Stephen Quinn, Stem Cell and Medical Device Entrepreneur, Dies Suddenly at 46 - 6.30.09
- Stephen Quinn, an emerging biotech and medical device entrepreneur in the Northwest, died suddenly at his home in Redmond, WA on Sunday. He was 46.
The League of Extraordinary Stem Cell Biologists - 6.30.09
- What it's like to be three scientists from the Harvard Stem Cell Institute: young, brilliant, fawned over by multimillionaire investors, courted by universities and corporations around the world, and forever racing—sometimes as teammates, sometimes as rivals—to change medicine as we know it.
LA doctors hope stem cells can heal injured heart - 6.30.09
- Doctors at a Los Angeles-based hospital have injected a heart patient with specialized stem cells grown from his own heart tissue in an attempt to reverse scarring after a heart attack.
Spitzer reports to the people - 6.30.09
- Spitzer’s report states an first-time investment of $60 million in the Empire State Stem Cell Trust Fund will promote innovation, promote medical advances and build an industry with substantial growth potential. The stem cell plan could stretch 11 years and garner $600 million total.
0 comments:
Post a Comment